Biologics for Reducing Cardiovascular Risk in Psoriasis Patients
Psoriasis is a chronic inflammatory skin disease with a high prevalence of cardiovascular disease (CVD), obesity, dyslipidemia, hypertension, diabetes mellitus, and metabolic syndrome. Among them, CVD is the most common cause of morbidity and mortality in psoriasis patients. Since CVD is associated...
Main Authors: | Hitoshi Terui, Yoshihide Asano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/3/1162 |
Similar Items
-
Reducing cardiovascular burden in psoriasis patients by using specific therapies – How close are we?
by: Claudia Andreea Palcau, et al.
Published: (2022-09-01) -
Old and New Biological Therapies for Psoriasis
by: Kirsten Rønholt, et al.
Published: (2017-11-01) -
Psoriasis as a risk factor of cardiovascular diseases
by: Olivia Rita Komorowska, et al.
Published: (2014-11-01) -
Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
by: Jiangluyi Cai, et al.
Published: (2021-11-01) -
A nomogram diagnostic cardiovascular disease in patients with erythrodermic psoriasis in Chinese
by: Yue-Min Zou, et al.
Published: (2023-06-01)